The NLC Health Impact Fund
Your access to the €10 trillion healthcare revolution
![](https://cdn.prod.website-files.com/664356b5a2e4f1e357ace733/66cf63bcd3b7216d3c9c5984_jump%20(1).webp)
![](https://cdn.prod.website-files.com/664356b5a2e4f1e357ace733/66d5cba1cbc55edeca9cb4a9_Frame%2021.png)
Why invest in healthcare
A shortage of healthcare professionals and an aging population: healthcare is one of the biggest challenges of our time. Yet the toughest challenges can turn into the most rewarding investments.
Your safest gateway to unlock the potential of this €10 trillion market is the NLC Health Impact Fund.
Why invest in the nlc health impact fund
Instead of investing in a single venture, you invest in the NLC Health Impact Fund, the newest flagship fund of the world's largest healthtech venture builder. You invest in a portfolio of 80-90 ventures from pre-seed to Series A/B and provides you access to healthcare innovations originating from world-renowned universities, hospitals and corporates, that are carefully vetted, supported and scaled by NLC.
![](https://cdn.prod.website-files.com/664356b5a2e4f1e357ace733/66cf626d3719bd54a3192af9_hif-banner-01.webp)
the benefits of investing in our fund
the numbers
Get in touch and explore the opportunities
![](https://cdn.prod.website-files.com/664356b5a2e4f1e357ace733/6697cd6638726938567d1f37_man.jpg)
A selection of ventures in
the NLC health impact fund
ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.
![Charm](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66544c1f27164acf4586cb8a_6650b057c1e0956317c1fa1e_charm2_720.webp)
OCCLUNOVA introduces a novel solution for chronic atrial fibrillation (AF), a condition affecting millions worldwide where the heart's upper chambers beat irregularly. Their implantable device aims to prevent strokes associated with AF by sealing off the left atrial appendage (LAA), where blood clots often form. Unlike traditional methods, which can cause complications due to their rigid frame, OccluNova's design uses a flexible balloon to fully seal the LAA. This innovative approach minimizes risks like pericardial effusions and incomplete closure, offering a safer option for AF patients.
![Occlunova](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66544c227dae5dc38c340f03_665067b9e5b9b2928eb97854_occlunova.webp)
Nicolab tackles the challenge of stroke diagnosis and treatment by offering computational support through their portfolio of six algorithms. These algorithms analyze radiological images of acute stroke patients, providing fast and objective interpretation for physicians. With stroke affecting millions annually and significant economic burdens, Nicolab's solution improves decision-making speed and accuracy, allowing clinicians to assess stroke severity objectively and make timely treatment decisions.
![Nicolab](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66544c215fd6de2e75fec02a_66507f65c30a1c7aca9721d1_nicolan.webp)
Implant Preservation Devices has developed a handheld device to tackle a common problem after joint replacement surgeries prosthetic joint infections (PJI). This device applies heat to implants using induction, effectively targeting and eliminating bacteria that cause these infections. By reducing the risk of recurrent infections, it offers a quick, sterile, and convenient treatment option during surgery, potentially benefiting patients beyond just those undergoing joint replacements.
![Implant Preservation Devices (IPD)](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/665462836b0929cee64e4ecf_Screenshot.webp)
NLC's venture, Profionics, advances Cardiff University's sepsis research with a biomarker test combining AI, gene expression, and metabolic analysis for rapid, accurate diagnosis. This test, which works in under 30 minutes with a drop of blood, surpasses traditional methods by quickly identifying those needing antibiotics and reducing unnecessary use, thus combating antimicrobial resistance and saving lives. Particularly impactful in neonatal care, it ensures timely detection critical for newborn survival. Founded by NLC, Cardiff University, and CEO Darren Fergus, Profionics leverages extensive research and a blood sample BioBank, positioning itself as a leader in host response diagnostic testing.
![Profionics](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66714a926117c55b4250b91d_profionics.webp)
Scinvivo introduces a solution for bladder cancer diagnosis with its imaging catheter, providing real-time, cross-sectional tissue images. Traditional methods often lead to unnecessary surgeries and missed tumors. By utilizing Optical Coherence Tomography technology, Scinvivo's catheter offers high-resolution imaging, enabling urologists to accurately diagnose bladder conditions. This approach reduces unnecessary surgeries but also enhances diagnostic accuracy, improving patient outcomes.
![Scinvivo](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66c840afb7ec0bed549e7391_IMG_0668.webp)
Laparoscopic surgery, while effective, faces limitations in low-resource areas due to cost and sustainability concerns associated with CO2 insufflation. Gasless laparoscopy provides an alternative, that are costly and difficult to use. To address these challenges, LORESA has developed an affordable and user-friendly gasless laparoscopy retractor, designed with input from surgeons worldwide, offering improved usability and cost-effectiveness. This innovation, aims to democratize laparoscopic techniques, benefiting rural hospitals and developing communities.
![Loresa](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66544c211022aab15146fe81_6650ae7b6b05ce5e4a6dda52_loresa.webp)
Introducing Liftya, a solution for shoulder instability. Developed with a patented spherical hinge mechanism, Liftya mimics the natural shoulder joint movement, offering stability and full range of motion. Unlike traditional braces, Liftya promotes motor recovery and independence, reducing pain and healthcare costs for patients.
![Liftya](https://cdn.prod.website-files.com/66436b3334541a4f2174a307/66544c21eedb5b2c5b657038_6654390a9ede394224fc5db3_Liftya%2520proto%2520pic%2520for%2520NLC%2520branding.webp)
Key considerations
As with all investments carrying risk, the value of your investment in NLC and its Health Impact Fund could be lost, in full or in part due to unexpected developments. Some of the key risks are listed below. Prospective investors are advised to consult the Information Memorandum of this Fund.
Restricted tradeability
As a closed-end fund, the interests are not freely tradeable. If an investor wishes to sell their fund holdings before the end of the 10-year term, their obtained returns might be negatively affected or the interests might not be tradable or will only be tradable to a limited extent because of lack of another person acquiring their interests. Investors could, thus, be bound to this investment longer than expected or desired.
Start-up risk
The Fund invests in healthtech startups, which are inherently of high risk. Several of the portfolio companies in which the Fund will invest will not be able to turn their current projects into fully commercialized products certified for medical use, negatively affecting the value of the investment.
Market risk
Many of the portfolio companies are projected to need one or more follow-on financing rounds to successfully launch their product on the market. While the fund itself can, inmost instances, also provide this follow-on financing, such investments always need to be matched by external investors. If the portfolio companies are unable to secure this funding, it might lead to a delay or a lack of sources to continue the developmental trajectories of one or more portfolio companies.
Insights
This webpage is a marketing material which has been prepared by NLC Fund Management B.V. (‘NLC’) with the purpose of sharing relevant information concerning the funds under their management. It does not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, which will only be made by means of an information memorandum and/or subscription documents. You may not rely on this webpage as the basis upon which to make an investment decision. This webpage does not purport to be complete on any topic addressed. NLC has not verified or analyzed the information included in this webpage for accuracy or completeness. NLC shall not bear any liability for the information contained in, or any omissions from, this webpage.
![](https://cdn.prod.website-files.com/664356b5a2e4f1e357ace733/66cef657bcf1b3a4766ada4c_risk-badge.webp)